Completed PHASE4 INTERVENTIONAL 2-arm NCT02643147

Loop Diuretic Dosage in Patients With Acute Heart Failure and Renal Failure: Conventional Versus Carbohydrate Antigen 125-guided Therapy (IMPROVE-HF) (IMPROVE-HF)

Sponsor: Fundación para la Investigación del Hospital Clínico de Valencia

Interventions CA125 guided strategy Conventional Strategy

Updated 7 times since 2017 Last updated: Feb 11, 2018 Started: Jan 31, 2015 Primary completion: Jan 30, 2017 Completion: Jan 30, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Heart Failure and is currently completed. Fundación para la Investigación del Hospital Clínico de Valencia leads this study, which shows 7 recorded versions since 2015 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Mar 2018 — Jun 2018 [monthly]

Completed PHASE4

Status: Unknown Status → Completed

▶ Show 2 earlier versions

Feb 2018 — Mar 2018 [monthly]

Unknown Status PHASE4

Status: Recruiting → Unknown Status
Jan 2017 — Feb 2018 [monthly]

Recruiting PHASE4

First recorded

Jan 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fundación para la Investigación del Hospital Clínico de Valencia

Data source: Fundación para la Investigación del Hospital Clínico de Valencia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Valencia, Spain